Sign inJoin waitlistJoin the waitlist

Michael Zelefsky

Director, Fellowship, Department of Radiation Oncology · NYU Grossman School of Medicine

Credentials: · · · ·

History

Academic & Faculty Affairs Department of Radiation Oncology · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine
Present

Hackensack University Medical Center
1986–1991
Memorial Sloan-Kettering Hospital
1985–1990
Albert Einstein College of Medicine
1982–1986

Research

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
European Urology · 2016 · 1,061 citations
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
International journal of radiation oncology · 1998 · First of 10 authors · 769 citations
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
Journal of Clinical Oncology · 2007 · 728 citations

MK
Marisa Kollmeier
78 papers
Zvi Fuks
70 papers
SL
Steven Leibel
64 papers
Yoshiya Yamada
54 papers
DK
Dennis Kraus
41 papers
Jatin Shah
38 papers
Sean McBride
36 papers
David Pfister
35 papers · 1 as a fellow
SW
Suzanne Wolden
30 papers
LH
Louis Harrison
29 papers
Daniel Spratt
26 papers · 18 as a resident
NL
Nancy Lee
25 papers

Clinical trials

Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
Principal investigator · Recruiting · Phase 2
NYU Langone Health
2026–2029
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
Principal investigator · Recruiting
NYU Langone Health
2025–2030
Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy
Principal investigator · Recruiting
NYU Langone Health
2024–2029
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
Principal investigator · Recruiting · Phase 2
NYU Langone Health
2024–2031